Specjalistyczny Niepubliczny Zaklad Opieki Zdrowotnej Alergologia Plus Osrodek Diagnostyki I Terapii Uczulen — Clinical Trial Site

39 Registered trials

12 Currently recruiting

Organisation

Specjalistyczny Niepubliczny Zaklad Opieki Zdrowotnej Alergologia Plus Osrodek Diagnostyki I Terapii Uczulen

Location

Poznan, Poland

Identifier

ORG-100033122

Address

Ul. Tomasza Drobnika 49, 60-693, Poland

Departments

#5754: Allergology
9503
Alergologia Plus Sp. zo.o Osrodek Diagnostyki i Terapii
N/A
NA
Ośrodek Alergologia Plus
Osrodek Diagnostyki i Terapii
Ośrodek Diagnostyki i Terapii Uczuleń
SNZOZ "Alergologia Plus" Ośrodek Diagnostyki i Terapii Uczuleń
SNZOZ Ośrodek Diagnostyki i Terapii Uczuleń Alergologia Plus
Specjalistyczny Niepubliczny Zaklad Opieki Zdrowotnej Alergologia Plus Osrodek Diagnostyki I Terapi
Specjalistyczny Niepubliczny Zaklad Opieki Zdrowotnej Alergologia Plus Osrodek Diagnostyki I Terapii
Specjalistyczny Niepubliczny Zakład Opieki Zdrowotnej „ALERGOLOGIA PLUS” Ośrodek Diagn
Specjalistyczny Niepubliczny Zakład Opieki Zdrowotnej Alergologia Plus
Specjalistyczny NZOZ Alergologia Plus Osrodek Diagnostyki I Terapii Uczulen

Clinical trials at this site (39)

Search interface

A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Ended

2022-502481-24-00 Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) 4 2024-05-23
A Phase 2 study to evaluate the efficacy and safety of RPT193 in adults with moderate-to-severe T2-high asthma who are partially controlled … Ended

2022-502854-16-00 Asthma 4 2023-11-26
Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy Ended

2022-502208-64-00 Asthma 4 2023-11-25
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria Ended

2022-503062-72-00 Chronic Spontaneous Urticaria 4 2023-11-23
A Multi-national Phase IIIb Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years o… Ended

2023-509833-38-00 Birch Pollen-induced Allergic Rhinoconjunctivitis 5 2023-09-20
This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis Ended

2023-504869-23-00 Dermatitis atopic 11 2023-05-31
A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-2) Ended

2023-507665-25-00 Severe Eosinophilic asthma 5 2023-04-25
Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended

2022-501063-41-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2023-04-20
Dose ranging study of amlitelimab in adult participants with moderate-to-severe asthma Ended

2024-510641-33-00 Asthma 4 2023-01-17
A study comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF5993 With the Fixed Dose Dual Combination CHF153… Ended

2023-510172-31-00 Chronic obstructive pulmonary disease (COPD) 5 2022-04-22
Study to assess efficacy, safety, and tolerability of Tozorakimab in patients with symptomatic chronic obstructive pulmonary disease (COPD) … Ended

2023-503572-24-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2022-03-02
The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy Ended

2023-510174-13-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2021-06-17
The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD) Ended

2023-510175-60-00 Chronic obstructive pulmonary disease (COPD) and Chron 5 2021-06-16
"A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with … Ended

2023-505787-11-00 Severe and inadequately controlled asthma 5 2021-04-29
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent Exace… Ended

2022-503050-39-00 Moderate to Very Severe Chronic Obstructive Pulmonary D 5 2019-11-12